Critical analysis of the immune tolerance phase of chronic HBV infection: Natural history and diagnosis

Current Hepatitis Reports

Volumn 7, Issue 1, 2008, Pages 5-11

  Kao, Jia Horng ^b   Chen, Ding Shinn ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CD4 ANTIGEN; CD45RO ANTIGEN; HEPATITIS B(E) ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; INTERLEUKIN 2 RECEPTOR ALPHA; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; BLOOD LEVEL; DISEASE COURSE; GENOTYPE; HAPLOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HLA SYSTEM; HUMAN; IMMUNOLOGICAL TOLERANCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NONHUMAN; OUTCOME ASSESSMENT; PATIENT MONITORING; REVIEW; SEROCONVERSION; VIRUS MUTANT; VIRUS REPLICATION;

EID: 45349094209     PISSN: 15403416     EISSN: 15410706     Source Type: Journal    
DOI: 10.1007/s11901-008-0015-1     Document Type: Review

References (41)

1. Kao JH, Chen DS: Global control of hepatitis B virus infection. Lancet Infect Dis 2002, 2:395-403.
2. Kao JH, Chen DS: The natural history of hepatitis B virus infection. In Hepatitis B Virus. Edited by Lai CL, Locarnini S. London: International Medical Press Ltd.; 2002:161-172.
3. Lau JY, Wright TL: Molecular virology and pathogenesis of hepatitis B. Lancet 1993, 342:1335-1340.
4. Chu CM, Liaw YF: Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion. J Viral Hepat 2007, 14:147-152.
5. Keeffe EB, Dieterich DT, Han SH, et al.: A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006, 4:936-962.
6. • Iloeje UH, Yang HI, Su J, et al.: Predicting liver cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006, 130:678-686. This important population-based prospective study indicates that a high serum HBV DNA level in HBV carriers aged 30 to 65 years increases the risk of progression to cirrhosis after more than 10 years of follow-up.
7. •• Chen CJ, Yang HI, Su J, et al.: Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006, 295:65-73. This landmark REVEAL-HBV study documents that the higher the serum HBV DNA level at entry, the higher the risk of HCC over time in HBV carriers older than 30 years.
8. • Iloeje UH, Yang HI, Jen CL, et al.: Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-Hepatitis B Virus Study Group: Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol 2007, 5:921-931. This study indicates that chronic HBV infection is associated with excess mortality risk and that this risk is strongly correlated with high serum HBV DNA levels.
9. Kao JH: Hepatitis B viral genotypes: clinical relevance and molecular characteristics. J Gastroenterol Hepatol 2002, 17:643-650.
10. • Kao JH, Chen DS: HBV genotypes: epidemiology and implications regarding natural history. Curr Hepat Rep 2006, 5:5-13. An excellent review of the epidemiology of HBV genotypes and their implications on the natural history of HBV infection.
11. • Liu CJ, Kao JH, Chen DS: Therapeutic implications of hepatitis B virus genotypes. Liver Int 2005, 25:1097-1107. A comprehensive review of the implications of HBV genotypes on the treatment of chronic HBV infection.
12. Stevens CE, Beasley RP, Tsui J, Lee WC: Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 1975, 292:771-774.
13. Chu CM, Liaw YF: Intrahepatic distribution of hepatitis B surface and core antigens in chronic hepatitis B virus infection. Hepatocyte with cytoplasmic/membranous hepatitis B core antigen as a possible target for immune hepatocytolysis. Gastroenterology 1987, 92:220-225.
14. Liaw YF, Yang SS, Chen TJ, Chu CM: Acute exacerbation in hepatitis B e antigen positive chronic type B hepatitis. A clinicopathological study. J Hepatol 1985, 1:227-233.
15. Chu CM, Liaw YF: HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology 2007, 45:1187-1192.
16. Kao JH, Chen PJ, Lai MY, Chen DS: Occult hepatitis B virus infection and clinical outcomes of patients with chronic hepatitis C. J Clin Microbiol 2002, 40:4068-4071.
17. Kao JH, Chen PJ, Lai MY, Chen DS: Sequence analysis of pre-S/surface and pre-core/core promoter genes of hepatitis B virus in chronic hepatitis C patients with occult HBV infection. J Med Virol 2002, 68:216-220.
18. Chen YC, Sheen IS, Chu CM, Liaw YF: Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 2002, 123:1084-1089.
19. Huo TI, Wu JC, Lee PC, et al.: Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis. Hepatology 1998, 28:231-236.
20. Xunrong L, Yan AW, Liang R, Lau GK: Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy - pathogenesis and management. Rev Med Virol 2001, 11:287-299.
21. Hadziyannis SJ, Vassilopoulos D: Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001, 34:617-624.
22. Yuen MF: Revisiting the natural history of chronic hepatitis B: impact of new concepts on clinical management. J Gastroenterol Hepatol 2007, 22:973-976.
23. Milich D, Liang TJ: Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. Hepatology 2003, 38:1075-1086.
24. Huang LR, Wu HL, Chen PJ, Chen DS: An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection. Proc Natl Acad Sci U S A 2006, 103:17862-17867.
25. Stoop JN, van der Molen RG, Baan CC, et al.: Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 2005, 41:771-778.
26. •• Ni YH, Chang MH, Chen PJ, et al.: Viremia profiles in children with chronic hepatitis B virus infection and spontaneous e antigen seroconversion. Gastroenterology 2007, 132:2340-2345. The first study to demonstrate the time sequences of viremia and ALT profiles from the immune tolerance phase to the immune clearance phase in child HBV carriers.
27. • Liu CJ, Chen PJ, Lai MY, et al.: Viral factors correlate with hepatitis B e antigen seroconverson in patients with chronic hepatitis B. Liver Int 2006, 26:949-955. An important study showing the viremia profile and serial changes of precore/core promoter sequences before and after HBeAg seroconversion in adult HBV carriers.
28. • Andreani T, Serfaty L, Mohand D, et al.: Chronic hepatitis B virus carriers in the immunotolerant phase of infection: histologic findings and outcome. Clin Gastroenterol Hepatol 2007, 5:636-641. An important study confirming that adult HBV carriers in the immune tolerance phase have minimal histologic change and that liver biopsy is probably not necessary in this population.
29. •• Hui CK, Leung N, Yuen ST, et al.: Hong Kong Liver Fibrosis Study Group: Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology 2007, 46:395-401. The first study to demonstrate that disease progression in adult HBV carriers who remain in the immune tolerance phase is minimal.
30. Chu CJ, Hussain M, Lok AS: Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology 2002, 122:1756-1762.
31. Kao JH, Chen PJ, Lai MY, Chen DS: Hepatitis B virus genotypes and spontaneous hepatitis B e antigen seroconversion in Taiwanese hepatitis B carriers. J Med Virol 2004, 72:363-369.
32. • Yuen MF, Wong DK, Zheng BJ, et al.: Difference in T helper responses during hepatitis flares in hepatitis B e antigen (HBeAg)-positive patients with genotypes B and C: implication for early HBeAg seroconversion. J Viral Hepat 2007, 14:269-275. An interesting study showing that HBV genotype B and C patients have different T-helper cell responses in the immune clearance phase.
33. Gunther S, Fischer L, Pult I, et al.: Naturally occurring variants of hepatitis B virus. Adv Virus Res 1999, 52:125-137.
34. Hunt CM, McGill JM, Allen MI, Condreay LD: Clinical relevance of hepatitis B viral mutations. Hepatology 2000, 31:1037-1044.
35. Okamoto H, Tsuda F, Akahane Y, et al.: Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol 1994, 68:8102-8110.
36. Kim HC, Nam CM, Jee SH, et al.: Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ 2004, 328:983-988.
37. Prati D, Taioli E, Zanella A, et al.: Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002, 137:1-10.
38. Lok AS, McMahon BJ: Chronic hepatitis B. Hepatology 2007, 45:507-539.
39. Yuen MF, Yuan HJ, Wong DK, et al.: Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut 2005, 54:1610-1614.
40. • Lin CL, Liao LY, Liu CJ, et al.: Hepatitis B viral factors in HBeAg-negative carriers with persistently normal serum alanine aminotransferase levels. Hepatology 2007, 45:1193-1198. The first study to provide a biologic basis for the observation that HBV carriers with high-normal ALT levels at entry have a higher risk of disease progression than do those with low-normal ALT levels during follow-up.
41. Wu JF, Chen CH, Hsieh RP, et al.: HLA typing associated with hepatitis B e antigen seroconversion in children with chronic hepatitis B virus infection: a long-term prospective sibling cohort study in Taiwan. J Pediatr 2006, 148:647-651.